{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:52:28Z","timestamp":1781632348663,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thyroid Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Graves\u2019 orbitopathy (GO) is an autoimmune disease of the orbit that occurs most often in relation to autoimmune. The clinical picture varies and is dependent on many risk factors, especially age, antibody levels and the quality of control of thyroid function. This study aimed to (1) compare the clinical characteristics of pediatric and adult Graves\u2019 orbitopathy (GO), (2) identify factors associated with remission in pediatric GO, and (3) assess the influence of thyroid treatment modality on TRAb dynamics in pediatric patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed the medical records of all pediatric patients with GO (&lt;\u200918\u2009years) and compared the results with those of a random sample of 482 (18\u201350\u2009years old) adult patients from the Graves\u2019 Orbitopathy Database (GODE), which includes 4260 patients from our tertiary referral center. A subcohort analysis of pediatric GO patients receiving definitive (surgical) thyroid or medical thyroid treatment was conducted. Risk stratification for remission in pediatric GO patients with the help of univariate as well as multiple logistic regression for different variables, including the serological laboratory results of Free Triiodothyronine (FT-3), Free Thyroxine (FT-4), TSH-receptor autoantibodies (TRAb) and antithyroglobulin antibodies (anti-TG), was conducted. Only those with complete data sets were included in the statistical analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Clinical presentation varied significantly between pediatric and adult patients, with children showing mostly mild manifestations (81% vs. 48.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), resulting in a much lower need for anti-inflammatory treatments and rehabilitative surgery. Univariate analyses revealed a significantly decreased probability of remission in nonthyroidectomized pediatric GO patients with high FT-3 or TRAb levels at the first clinical presentation (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). The surgically managed pediatric GO cohort had higher initial TRAb levels but quicker TRAb normalization over time and higher serological remission rates (TRAb\u2009&lt;\u20091,75UI) (38% vs 74%, respectively) than did the nonthyroidectomized pediatric subgroup at the last clinical presentation. Interestingly, pediatric GO patients in whom antithyroid drug (ATD) therapy was initiated only at or after their first clinical visit at our referral center presented greater clinical activity and prolonged TRAb normalization duration than patients who were already receiving anti-thyroid drugs did (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.005).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>FT-3 and TRAb levels are also prognostic factors for remission in pediatric patients with GO. International guidelines for the management of pediatric GO have divided opinions on the duration of anti-thyroid drugs prior to definitive surgical thyroid therapy (2\u20135\u2009years). Our results highlight the prognostic role of serum biomarkers (FT-3, FT-4, TSH-receptor autoantibodies (TRAb)) at first clinical presentation and hint to positive effects of thyroidectomy in pediatric GO patients with high FT-3 or TRAb and therefore unlikely remission in the conservative treated subpopulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13044-026-00286-7","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:27:13Z","timestamp":1769092033000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pediatric Graves\u2019 orbitopathy: TRAb and FT-3 are also prognostic factors in children\u2014A tertiary center study"],"prefix":"10.1186","volume":"19","author":[{"given":"Karim","family":"Al-Ghazzawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oeverhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arber","family":"Rama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula","family":"Kiewert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Bechrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"issue":"4","key":"286_CR1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S0002-9394(14)72666-2","volume":"120","author":"GB Bartley","year":"1995","unstructured":"Bartley GB, et al. The incidence of Graves\u2019 ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol. 1995;120(4):511\u201317","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"286_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/WNO.0000000000000132","volume":"34","author":"SJ Shan","year":"2014","unstructured":"Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34(2):177\u201385","journal-title":"J Neuroophthalmol"},{"issue":"10","key":"286_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1055\/s-0035-1555762","volume":"47","author":"RS Bahn","year":"2015","unstructured":"Bahn RS. Current insights into the pathogenesis of Graves\u2019 ophthalmopathy. Horm Metab Res. 2015;47(10):773\u201378","journal-title":"Horm Metab Res"},{"issue":"1","key":"286_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","volume":"6","author":"TF Davies","year":"2020","unstructured":"Davies TF, et al. Graves\u2019 disease. Nat Rev Dis Primers. 2020;6(1):52","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"286_CR5","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1210\/jc.2016-1315","volume":"101","author":"CC Krieger","year":"2016","unstructured":"Krieger CC, et al. TSH\/IGF-1 receptor cross talk in Graves\u2019 ophthalmopathy Pathogenesis. J Clin Endocrinol Metab. 2016;101(6):2340\u201347","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"286_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1089\/thy.2022.0173","volume":"32","author":"YP Hai","year":"2022","unstructured":"Hai YP, et al. A multicenter, single-blind, case-control, Immunohistochemical study of orbital tissue in thyroid eye disease. Thyroid. 2022;32(12):1547\u201358","journal-title":"Thyroid"},{"issue":"10","key":"286_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1055\/s-0035-1559633","volume":"47","author":"SA Morshed","year":"2015","unstructured":"Morshed SA, Davies TF. Graves\u2019 disease mechanisms: the role of stimulating, blocking, and cleavage region TSH receptor antibodies. Horm Metab Res. 2015;47(10):727\u201334","journal-title":"Horm Metab Res"},{"issue":"6","key":"286_CR8","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"S Tsui","year":"2008","unstructured":"Tsui S, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease. J Immunol. 2008;181(6):4397\u2013405","journal-title":"J Immunol"},{"issue":"3","key":"286_CR9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1210\/jc.2014-3566","volume":"100","author":"CC Krieger","year":"2015","unstructured":"Krieger CC, et al. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves\u2019 disease immunoglobins. J Clin Endocrinol Metab. 2015;100(3):1071\u201377","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"286_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1055\/a-1525-2070","volume":"53","author":"M Stohr","year":"2021","unstructured":"Stohr M, et al. Predicting the course of Graves\u2019 orbitopathy using serially measured TSH-Receptor autoantibodies by automated binding immunoassays and the functional bioassay. Horm Metab Res. 2021;53(7):435\u201343","journal-title":"Horm Metab Res"},{"issue":"13","key":"286_CR11","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.1167\/iovs.18-25466","volume":"59","author":"S Plohn","year":"2018","unstructured":"Plohn S, et al. CD40 enhances sphingolipids in orbital fibroblasts: potential role of sphingosine-1-phosphate in inflammatory T-Cell migration in Graves\u2019 orbitopathy. Invest Ophthalmol Vis Sci. 2018;59(13):5391\u201397","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"286_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1530\/eje.1.01991","volume":"153","author":"GE Krassas","year":"2005","unstructured":"Krassas GE, Segni M, Wiersinga WM. Childhood Graves\u2019 ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol. 2005;153(4):515\u201321","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"286_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4103\/sjopt.sjopt_47_22","volume":"37","author":"J Jankauskiene","year":"2023","unstructured":"Jankauskiene J, Jarusaitiene D. Symptoms and signs of dry eye in children with Graves\u2019 ophthalmopathy. Saudi J Ophthalmol. 2023;37(2):149\u201353","journal-title":"Saudi J Ophthalmol"},{"key":"286_CR14","doi-asserted-by":"crossref","unstructured":"Kahaly GJ, et al. European thyroid association guideline for the management of Graves\u2019Hyperthyroidism. Eur Thyroid J. 2018, 2018;7(4):167\u201386","DOI":"10.1159\/000490384"},{"key":"286_CR15","doi-asserted-by":"crossref","unstructured":"Bettendorf M. Thyroid disorders in children from birth to adolescence. Eur J Nucl Med Mol Imag. 2002;29 (Suppl 2) p. S439\u201346","DOI":"10.1007\/s00259-002-0905-3"},{"issue":"2","key":"286_CR16","first-page":"234","volume":"7","author":"AI Gogakos","year":"2010","unstructured":"Gogakos AI, Boboridis K, Krassas GE. Pediatric aspects in Graves\u2019 orbitopathy. Pediatr Endocrinol Rev. 2010;7 (Suppl, 2):234\u201344","journal-title":"Pediatr Endocrinol Rev"},{"key":"286_CR17","doi-asserted-by":"crossref","unstructured":"Mooij CF, et al. 2022 European thyroid association guideline for the management of pediatric Graves\u2019 disease. Eur Thyroid J. 2022;11(1)","DOI":"10.1530\/ETJ-21-0073"},{"issue":"10","key":"286_CR18","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1515\/jpem-2016-0122","volume":"29","author":"J Szczapa-Jagustyn","year":"2016","unstructured":"Szczapa-Jagustyn J, Gotz-Wieckowska A, Kociecki J. An update on thyroid-associated ophthalmopathy in children and adolescents. J Pediatr Endocrinol Metab. 2016;29(10):1115\u201322","journal-title":"J Pediatr Endocrinol Metab"},{"key":"286_CR19","doi-asserted-by":"crossref","unstructured":"Ionescu IC, et al. Pediatric Graves\u2019 orbitopathy: a multicentre study. Acta Ophthalmol. 2022, 1348;100(6):e1340\u2013e","DOI":"10.1111\/aos.15084"},{"key":"286_CR20","doi-asserted-by":"crossref","unstructured":"Oeverhaus M, et al. How age affects Graves\u2019 orbitopathy-A tertiary center study. J Clin Med. 2024;13(1)","DOI":"10.3390\/jcm13010290"},{"issue":"4","key":"286_CR21","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, et al. The 2021 European group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol. 2021;185(4):G43\u201367","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"286_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/bjo.73.8.639","volume":"73","author":"MP Mourits","year":"1989","unstructured":"Mourits MP, et al. Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73(8):639\u201344","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"286_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, et al. Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf). 1997;47(1):9\u201314","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"286_CR24","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1365-2265.2004.02143.x","volume":"61","author":"AK Eckstein","year":"2004","unstructured":"Eckstein AK, et al. Clinical results of anti-inflammatory therapy in Graves\u2019 ophthalmopathy and association with thyroidal autoantibodies*. Clin Endocrinol. 2004;61(5):612\u201318","journal-title":"Clin Endocrinol"},{"issue":"4S Suppl 1","key":"286_CR25","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1097\/IOP.0000000000001137","volume":"34","author":"MR Chua","year":"2018","unstructured":"Chua MR, et al. Pediatric thyroid eye disease: clinical characteristics and orbital decompression outcomes. Ophthalmic Plast Reconstr Surg. 2018;34(4S Suppl 1):S52\u201355","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"286_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/01676830.2020.1831550","volume":"41","author":"B Sim","year":"2022","unstructured":"Sim B, et al. A retrospective study of pediatric thyroid eye disease: the Asian experience. Orbit. 2022;41(1):69\u201378","journal-title":"Orbit"},{"issue":"10","key":"286_CR27","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1210\/jc.2009-0747","volume":"94","author":"F Traisk","year":"2009","unstructured":"Traisk F, et al. Thyroid-associated ophthalmopathy after treatment for Graves\u2019 hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab. 2009;94(10):3700\u201307","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"286_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/EJE-07-0450","volume":"158","author":"P Laurberg","year":"2008","unstructured":"Laurberg P, et al. TSH-receptor autoimmunity in Graves\u2019 disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158(1):69\u201375","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"286_CR29","first-page":"2986","volume":"81","author":"O Torring","year":"1996","unstructured":"Torring O, et al. Graves\u2019 hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine-a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab. 1996;81(8):2986\u201393","journal-title":"Thyroid Study Group. J Clin Endocrinol Metab"},{"key":"286_CR30","doi-asserted-by":"publisher","first-page":"1160172","DOI":"10.3389\/fendo.2023.1160172","volume":"14","author":"M Oeverhaus","year":"2023","unstructured":"Oeverhaus M, et al. Influence of biological sex, age and smoking on Graves\u2019 orbitopathy - a ten-year tertiary referral center analysis. Front Endocrinol (lausanne). 2023;14:1160172","journal-title":"Front Endocrinol (lausanne)"},{"issue":"4","key":"286_CR31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1530\/eje.0.1320406","volume":"132","author":"B Winsa","year":"1995","unstructured":"Winsa B, et al. Retrospective evaluation of subtotal and total thyroidectomy in Graves\u2019 disease with and without endocrine ophthalmopathy. Eur J Endocrinol. 1995;132(4):406\u201312","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"286_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1046\/j.1365-2265.1999.00843.x","volume":"51","author":"C Marcocci","year":"1999","unstructured":"Marcocci C, et al. The course of Graves\u2019 ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol (Oxf). 1999;51(4):503\u201308","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"286_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1297\/cpe.26.29","volume":"26","author":"JSFPE Pharmaceutical Affairs","year":"2017","unstructured":"Pharmaceutical Affairs JSFPE, et al. Guidelines for the treatment of childhood-onset Graves\u2019 disease in Japan, 2016. Clin Pediatr Endocrinol. 2017;26(2):29\u201362","journal-title":"Clin Pediatr Endocrinol"},{"issue":"10","key":"286_CR34","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343\u2013421","journal-title":"Thyroid"},{"issue":"2","key":"286_CR35","doi-asserted-by":"publisher","first-page":"e70130","DOI":"10.1002\/oto2.70130","volume":"9","author":"M Aweeda","year":"2025","unstructured":"Aweeda M, et al. Risk factors and rates for hypocalcemia after pediatric thyroidectomy: a systematic review and meta-analysis. OTO Open. 2025;9(2):e70130","journal-title":"OTO Open"},{"key":"286_CR36","doi-asserted-by":"publisher","first-page":"101642","DOI":"10.1016\/j.bjorl.2025.101642","volume":"91","author":"FC Hojaij","year":"2025","unstructured":"Hojaij FC, et al. Thyroidectomy in children (small star, filled, small star, filled small star, filled). Braz J Otorhinolaryngol. 2025;91Suppl, 1: p. 101642","journal-title":"Braz J Otorhinolaryngol"},{"issue":"4","key":"286_CR37","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1210\/jc.2015-3644","volume":"101","author":"XG Vos","year":"2016","unstructured":"Vos XG, et al. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves\u2019. Hyperthyroidism. J Clin Endocrinol Metab. 2016;101(4):1381\u201389","journal-title":"Hyperthyroidism. J Clin Endocrinol Metab"},{"issue":"12","key":"286_CR38","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s40618-016-0516-7","volume":"39","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, et al. The phenotype of newly diagnosed Graves\u2019 disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J Endocrinol Invest. 2016;39(12):1445\u201351","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"286_CR39","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s40618-018-0918-9","volume":"41","author":"E Masiello","year":"2018","unstructured":"Masiello E, et al. Antithyroid drug treatment for Graves\u2019 disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest. 2018;41(12):1425\u201332","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"286_CR40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/thy.2006.16.295","volume":"16","author":"C Carella","year":"2006","unstructured":"Carella C, et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves\u2019 disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and\/or thyroid response modify during the observation period. Thyroid. 2006;16(3):295\u2013302","journal-title":"Thyroid"},{"issue":"2","key":"286_CR41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1055\/s-2004-814217","volume":"36","author":"M Schott","year":"2004","unstructured":"Schott M, et al. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves\u2019 disease. Horm Metab Res. 2004;36(2):92\u201396","journal-title":"Horm Metab Res"},{"issue":"4","key":"286_CR42","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1055\/a-1373-5523","volume":"53","author":"M Stohr","year":"2021","unstructured":"Stohr M, et al. Predicting the relapse of hyperthyroidism in treated Graves\u2019 disease with orbitopathy by serial measurements of TSH-Receptor autoantibodies. Horm Metab Res. 2021;53(4):235\u201344","journal-title":"Horm Metab Res"},{"issue":"8","key":"286_CR43","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s40618-023-02044-0","volume":"46","author":"A Brancatella","year":"2023","unstructured":"Brancatella A, et al. In Graves\u2019 disease, thyroid autoantibodies and ultrasound features correlate with distinctive histological features. J Endocrinol Invest. 2023;46(8):1695\u2013703","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"286_CR44","doi-asserted-by":"publisher","first-page":"162365","DOI":"10.1016\/j.jpedsurg.2025.162365","volume":"60","author":"DJ van de Berg","year":"2025","unstructured":"van de Berg DJ, et al. Quantified fluorescence Imaging for the perfusion of the parathyroid glands of children (FLUOPATCH): a Multicenter, proof-of-concept study. J Pediatr Surg. 2025;60(8):162365","journal-title":"J Pediatr Surg"},{"issue":"6","key":"286_CR45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI, et al. Randomized trial of thymectomy in Myasthenia Gravis. N Engl J Med. 2016;375(6):511\u201322","journal-title":"N Engl J Med"}],"container-title":["Thyroid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-026-00286-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13044-026-00286-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-026-00286-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:57:38Z","timestamp":1781629058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13044-026-00286-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["286"],"URL":"https:\/\/doi.org\/10.1186\/s13044-026-00286-7","relation":{},"ISSN":["1756-6614"],"issn-type":[{"value":"1756-6614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Commission of the University of Essen (reference number: 21\u201310250-BO). All the data were anonymized, and the requirement for informed consent was waived because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval declaration & consent to participate declaration"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}